Osteopontin (OPN) is a glycosylated phosphoprotein that is involved in a variety of biological processes such as inflammation, immune response, cell adhesion, and tissue remodeling. OPN is overexpressed in many diseases, including cancer, autoimmune diseases, and cardiovascular diseases, making it an attractive target for therapeutic intervention. OPN inhibitors have been developed to block the biological activity of OPN and potentially treat these diseases. In this answer, we will discuss the most promising OPN inhibitors currently in development.
OPN-305
OPN-305 is a humanized monoclonal antibody that targets OPN. It is being developed by Omeros Corporation for the treatment of a variety of diseases, including cancer, autoimmune diseases, and cardiovascular diseases. OPN-305 has shown promising results in a phase II clinical trial for the treatment of rheumatoid arthritis (RA) and is currently being evaluated in phase III trials for the treatment of severe COVID-19 pneumonia.
ATN-161
ATN-161 is a peptide that inhibits the binding of OPN to integrin receptors. It is being developed by Attenukine, Inc. for the treatment of cancer and fibrosis. ATN-161 has shown promising results in preclinical studies for the treatment of several types of cancer, including breast, prostate, and pancreatic cancer. It is currently being evaluated in phase I/II clinical trials for the treatment of advanced solid tumors.
Cilengitide
Cilengitide is a cyclic peptide that inhibits the binding of OPN to integrin receptors. It is being developed by Merck KGaA for the treatment of glioblastoma multiforme (GBM), a type of brain cancer. Cilengitide has shown promising results in phase II clinical trials for the treatment of GBM and is currently being evaluated in phase III clinical trials.
Sefralogix
Sefralogix is a small molecule inhibitor of OPN that is being developed by SeFAL Life Science AB for the treatment of cancer. Sefralogix has shown promising results in preclinical studies for the treatment of several types of cancer, including colorectal, breast, and prostate cancer. It is currently being evaluated in phase I clinical trials for the treatment of advanced solid tumors.
Etigilimab
Etigilimab is a monoclonal antibody that targets the receptor for OPN, CD44. It is being developed by BeiGene for the treatment of solid tumors. Etigilimab has shown promising results in phase I clinical trials for the treatment of advanced solid tumors and is currently being evaluated in phase II clinical trials.
BMS-986258
BMS-986258 is a monoclonal antibody that targets OPN. It is being developed by Bristol-Myers Squibb for the treatment of solid tumors. BMS-986258 has shown promising results in preclinical studies for the treatment of several types of cancer, including lung and breast cancer. It is currently being evaluated in phase I clinical trials for the treatment of advanced solid tumors.
2-deoxy-D-glucose (2-DG)
2-deoxy-D-glucose (2-DG) is a small molecule inhibitor of OPN that is being developed by the Indian Institute of Technology (IIT) Delhi for the treatment of cancer. 2-DG has shown promising results in preclinical studies for the treatment of several types of cancer, including breast and lung cancer. It is currently being evaluated in phase II clinical trials for the treatment of breast cancer.
In conclusion, there are several promising OPN inhibitors currently in development that have shown potential for the treatment of various diseases, including cancer, autoimmune diseases, and cardiovascular diseases. These inhibitors target OPN or its receptors and have shown promising results in preclinical and clinical studies. Further research is needed to fully understand the safety and efficacy of these inhibitors and to develop more effective treatments for these diseases.
